Trade Neurocrine Biosciences, Inc. - NBIX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.24 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Neurocrine Biosciences Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 110.11 |
| Open* | 110.14 |
| 1-Year Change* | 3.3% |
| Day's Range* | 109.68 - 110.83 |
| 52 wk Range | 89.04-129.29 |
| Average Volume (10 days) | 606.73K |
| Average Volume (3 months) | 15.46M |
| Market Cap | 10.59B |
| P/E Ratio | 62.35 |
| Shares Outstanding | 97.65M |
| Revenue | 1.67B |
| EPS | 1.74 |
| Dividend (Yield %) | N/A |
| Beta | 0.46 |
| Next Earnings Date | Oct 30, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Oct 3, 2023 | 110.11 | -0.80 | -0.72% | 110.91 | 111.66 | 108.52 |
| Oct 2, 2023 | 111.28 | -0.40 | -0.36% | 111.68 | 112.53 | 110.58 |
| Sep 29, 2023 | 112.39 | -1.98 | -1.73% | 114.37 | 115.14 | 111.82 |
| Sep 28, 2023 | 114.62 | 0.31 | 0.27% | 114.31 | 115.23 | 113.49 |
| Sep 27, 2023 | 114.90 | 0.70 | 0.61% | 114.20 | 115.80 | 114.13 |
| Sep 26, 2023 | 114.57 | 2.46 | 2.19% | 112.11 | 115.14 | 112.11 |
| Sep 25, 2023 | 113.55 | 0.55 | 0.49% | 113.00 | 114.46 | 112.27 |
| Sep 22, 2023 | 113.70 | 0.65 | 0.57% | 113.05 | 114.37 | 112.65 |
| Sep 21, 2023 | 113.08 | -0.81 | -0.71% | 113.89 | 114.79 | 112.70 |
| Sep 20, 2023 | 113.91 | 0.42 | 0.37% | 113.49 | 115.42 | 113.31 |
| Sep 19, 2023 | 114.71 | 3.04 | 2.72% | 111.67 | 114.91 | 111.66 |
| Sep 18, 2023 | 111.91 | -0.01 | -0.01% | 111.92 | 112.80 | 110.90 |
| Sep 15, 2023 | 112.36 | 0.26 | 0.23% | 112.10 | 113.46 | 111.46 |
| Sep 14, 2023 | 113.65 | -1.33 | -1.16% | 114.98 | 114.98 | 113.02 |
| Sep 13, 2023 | 113.92 | -3.04 | -2.60% | 116.96 | 117.36 | 113.92 |
| Sep 12, 2023 | 116.70 | 2.75 | 2.41% | 113.95 | 119.12 | 113.35 |
| Sep 11, 2023 | 109.54 | 1.13 | 1.04% | 108.41 | 109.63 | 107.36 |
| Sep 8, 2023 | 109.21 | 1.80 | 1.68% | 107.41 | 109.85 | 107.29 |
| Sep 7, 2023 | 108.36 | -1.41 | -1.28% | 109.77 | 110.32 | 108.05 |
| Sep 6, 2023 | 109.70 | 1.57 | 1.45% | 108.13 | 110.65 | 108.13 |
Neurocrine Biosciences, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, October 30, 2023 | ||
| Time (UTC) 11:30 | Country US
| Event Q3 2023 Neurocrine Biosciences Inc Earnings Release Q3 2023 Neurocrine Biosciences Inc Earnings ReleaseForecast -Previous - |
| Monday, February 5, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q4 2023 Neurocrine Biosciences Inc Earnings Release Q4 2023 Neurocrine Biosciences Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 1488.7 | 1133.5 | 1045.9 | 788.087 | 451.24 |
| Revenue | 1488.7 | 1133.5 | 1045.9 | 788.087 | 451.24 |
| Total Operating Expense | 1309.7 | 1031 | 901.3 | 715.804 | 414.345 |
| Selling/General/Admin. Expenses, Total | 751 | 583.3 | 433.3 | 354.062 | 248.932 |
| Research & Development | 463.8 | 328.1 | 275 | 200.042 | 160.524 |
| Operating Income | 179 | 102.5 | 144.6 | 72.283 | 36.895 |
| Interest Income (Expense), Net Non-Operating | 34.9 | -1.1 | -37.9 | -25.741 | -15.054 |
| Gain (Loss) on Sale of Assets | |||||
| Other, Net | |||||
| Net Income Before Taxes | 213.9 | 101.4 | 106.7 | 46.542 | 21.841 |
| Net Income After Taxes | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
| Net Income Before Extra. Items | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
| Net Income | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
| Income Available to Common Excl. Extra. Items | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
| Income Available to Common Incl. Extra. Items | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
| Diluted Net Income | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
| Diluted Weighted Average Shares | 98.9 | 97.9 | 97.8 | 95.732 | 95.386 |
| Diluted EPS Excluding Extraordinary Items | 1.56218 | 0.91522 | 4.16462 | 0.38662 | 0.22132 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | 2.08583 | 1.86564 | 5.38021 | 1.66815 | 0.22132 |
| Cost of Revenue, Total | 23.2 | 14.3 | 10.1 | 7.428 | 4.889 |
| Gross Profit | 1465.5 | 1119.2 | 1035.8 | 780.659 | 446.351 |
| Unusual Expense (Income) | 71.7 | 105.3 | 182.9 | 154.272 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 452.7 | 420.4 | 412 | 387.9 | 378.2 |
| Revenue | 452.7 | 420.4 | 412 | 387.9 | 378.2 |
| Cost of Revenue, Total | 11.5 | 8.5 | 7.7 | 6.1 | 4.8 |
| Gross Profit | 441.2 | 411.9 | 404.3 | 381.8 | 373.4 |
| Total Operating Expense | 379.1 | 534.6 | 308.6 | 300.1 | 393.5 |
| Selling/General/Admin. Expenses, Total | 221.8 | 242.7 | 182.9 | 186.3 | 182.8 |
| Research & Development | 145.8 | 139.5 | 118 | 107.7 | 135.9 |
| Operating Income | 73.6 | -114.2 | 103.4 | 87.8 | -15.3 |
| Interest Income (Expense), Net Non-Operating | 48 | 10.9 | 14.5 | 10.1 | -8 |
| Net Income Before Taxes | 121.6 | -103.3 | 117.9 | 97.9 | -23.3 |
| Net Income After Taxes | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
| Net Income Before Extra. Items | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
| Net Income | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
| Income Available to Common Excl. Extra. Items | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
| Income Available to Common Incl. Extra. Items | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
| Diluted Net Income | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
| Diluted Weighted Average Shares | 100.2 | 97.1 | 100.7 | 99 | 95.6 |
| Diluted EPS Excluding Extraordinary Items | 0.95309 | -0.78888 | 0.88381 | 0.69192 | -0.17678 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 0.95309 | 0.17441 | 0.88381 | 0.69192 | 0.29916 |
| Unusual Expense (Income) | 0 | 143.9 | 0 | 0 | 70 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 1453.5 | 972.8 | 1016.2 | 831.034 | 737.777 |
| Cash and Short Term Investments | 989.3 | 711.3 | 801 | 670.524 | 650.913 |
| Cash & Equivalents | 262.9 | 340.8 | 187.1 | 112.279 | 141.714 |
| Short Term Investments | 726.4 | 370.5 | 613.9 | 558.245 | 509.199 |
| Other Current Assets, Total | 79.1 | 45.5 | 30.1 | 16.647 | 18.594 |
| Total Assets | 2368.7 | 2072.5 | 1734.7 | 1306.04 | 993.151 |
| Property/Plant/Equipment, Total - Net | 145.6 | 155.8 | 127.4 | 116.278 | 33.869 |
| Property/Plant/Equipment, Total - Gross | 211.9 | 207.7 | 169.1 | 149.837 | 62.14 |
| Accumulated Depreciation, Total | -66.3 | -51.9 | -41.7 | -33.559 | -28.271 |
| Long Term Investments | 401.5 | 624.4 | 265.3 | 355.522 | 216.028 |
| Other Long Term Assets, Total | 330.9 | 319.5 | 325.8 | 3.206 | 5.477 |
| Total Current Liabilities | 537.7 | 245.8 | 186.5 | 565.287 | 88.233 |
| Accounts Payable | 46.214 | 38.381 | |||
| Accrued Expenses | 129.3 | 99.5 | 81.4 | 72.719 | 34.41 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 408.807 | 0 |
| Other Current Liabilities, Total | 3.3 | 3.5 | 7.5 | 37.547 | 15.442 |
| Total Liabilities | 660.9 | 698.5 | 608.5 | 669.117 | 512.386 |
| Total Long Term Debt | 0 | 335.1 | 317.9 | 0 | 388.496 |
| Other Liabilities, Total | 123.2 | 117.6 | 104.1 | 103.83 | 35.657 |
| Total Equity | 1707.8 | 1374 | 1126.2 | 636.923 | 480.765 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.1 | 0.1 | 0.1 | 0.092 | 0.091 |
| Additional Paid-In Capital | 2122.4 | 2011.4 | 1849.7 | 1768.12 | 1660.36 |
| Retained Earnings (Accumulated Deficit) | -406.8 | -635.8 | -725.4 | -1132.7 | -1177.76 |
| Other Equity, Total | -7.9 | -1.7 | 1.8 | 1.413 | -1.932 |
| Total Liabilities & Shareholders’ Equity | 2368.7 | 2072.5 | 1734.7 | 1306.04 | 993.151 |
| Total Common Shares Outstanding | 96.5 | 94.9 | 93.5 | 92.272 | 90.797 |
| Total Receivables, Net | 350 | 185.5 | 157.1 | 126.575 | 57.406 |
| Accounts Receivable - Trade, Net | 350 | 185.5 | 157.1 | 126.575 | 57.406 |
| Long Term Debt | 0 | 335.1 | 317.9 | 0 | 388.496 |
| Total Inventory | 35.1 | 30.5 | 28 | 17.288 | 10.864 |
| Payable/Accrued | 235.7 | 142.8 | 97.6 | ||
| Intangibles, Net | 37.2 | ||||
| Current Port. of LT Debt/Capital Leases | 169.4 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 1432.8 | 1453.5 | 1205.5 | 1019.3 | 1018.2 |
| Cash and Short Term Investments | 894.6 | 989.3 | 799.4 | 648.3 | 664.9 |
| Cash & Equivalents | 103.8 | 262.9 | 212.2 | 163.3 | 270.2 |
| Short Term Investments | 790.8 | 726.4 | 587.2 | 485 | 394.7 |
| Total Receivables, Net | 391.6 | 350 | 301.2 | 279 | 263.5 |
| Accounts Receivable - Trade, Net | 391.6 | 350 | 301.2 | 279 | 263.5 |
| Total Inventory | 33.4 | 35.1 | 37 | 29.3 | 29 |
| Other Current Assets, Total | 113.2 | 79.1 | 67.9 | 62.7 | 60.8 |
| Total Assets | 2359.8 | 2368.7 | 2143.4 | 2005.7 | 2144.5 |
| Property/Plant/Equipment, Total - Net | 147.2 | 145.6 | 150.5 | 159 | 158.6 |
| Long Term Investments | 380.3 | 401.5 | 457.5 | 489 | 632.3 |
| Other Long Term Assets, Total | 362.3 | 330.9 | 329.9 | 338.4 | 335.4 |
| Total Current Liabilities | 374.1 | 537.7 | 485.1 | 285.7 | 253.5 |
| Payable/Accrued | 355.7 | 347.6 | 297.8 | 265.7 | 235.9 |
| Accrued Expenses | 17.6 | 17.4 | 17.3 | 17.1 | 16.9 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.8 | 3.3 | 0.8 | 2.9 | 0.7 |
| Total Liabilities | 675.3 | 660.9 | 598.8 | 582.3 | 753.4 |
| Total Long Term Debt | 169.5 | 0 | 0 | 169 | 377.7 |
| Long Term Debt | 169.5 | 0 | 0 | 169 | 377.7 |
| Other Liabilities, Total | 131.7 | 123.2 | 113.7 | 127.6 | 122.2 |
| Total Equity | 1684.5 | 1707.8 | 1544.6 | 1423.4 | 1391.1 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Additional Paid-In Capital | 2170.5 | 2122.4 | 2054.3 | 1999.8 | 1947.7 |
| Retained Earnings (Accumulated Deficit) | -483.4 | -406.8 | -495.8 | -564.3 | -547.4 |
| Other Equity, Total | -2.7 | -7.9 | -14 | -12.2 | -9.3 |
| Total Liabilities & Shareholders’ Equity | 2359.8 | 2368.7 | 2143.4 | 2005.7 | 2144.5 |
| Total Common Shares Outstanding | 97.5 | 96.5 | 96.1 | 95.6 | 95.5 |
| Current Port. of LT Debt/Capital Leases | 0 | 169.4 | 169.2 | ||
| Intangibles, Net | 37.2 | 37.2 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
| Cash From Operating Activities | 339.4 | 256.5 | 228.5 | 152.054 | 101.364 |
| Cash From Operating Activities | 15.1 | 10.9 | 8.6 | 7.452 | 4.024 |
| Non-Cash Items | 217.6 | 135 | 161.2 | 107.349 | 77.986 |
| Cash Interest Paid | 6.6 | 8.6 | 11.6 | 11.644 | 11.644 |
| Changes in Working Capital | -67.4 | 16.7 | -37.9 | 0.241 | -1.757 |
| Cash From Investing Activities | -177.1 | -130.2 | 4.1 | -211.073 | -242.915 |
| Capital Expenditures | -16.5 | -23.4 | -10.9 | -14.748 | -24.812 |
| Other Investing Cash Flow Items, Total | -160.6 | -106.8 | 15 | -196.325 | -218.103 |
| Cash From Financing Activities | -234.3 | 27.4 | -157.8 | 27.313 | 29.53 |
| Issuance (Retirement) of Stock, Net | 44.7 | 27.5 | 29.1 | 27.313 | 29.53 |
| Issuance (Retirement) of Debt, Net | -279 | -0.1 | -186.9 | 0 | 0 |
| Net Change in Cash | -73.3 | 153.7 | 74.8 | -31.706 | -112.021 |
| Cash Taxes Paid | 14.4 | 5.1 | 15.3 | 0.507 | |
| Deferred Taxes | 19.1 | 4.3 | -310.7 | ||
| Amortization | 0.5 | ||||
| Foreign Exchange Effects | -1.3 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -76.6 | 154.5 | 65.5 | -3 | 13.9 |
| Cash From Operating Activities | -125.2 | 339.4 | 196.4 | 97.6 | -40.5 |
| Cash From Operating Activities | 4.1 | 15.1 | 11.2 | 7.2 | 3.3 |
| Deferred Taxes | -31.6 | 19.1 | 5.6 | -3.4 | -0.3 |
| Non-Cash Items | 35.5 | 217.6 | 180 | 147.1 | 18.3 |
| Changes in Working Capital | -57.5 | -67.4 | -65.9 | -50.3 | -75.7 |
| Cash From Investing Activities | -42.1 | -177.1 | -61.5 | -0.2 | -31.6 |
| Capital Expenditures | -8.5 | -16.5 | -14.7 | -16.4 | -7.6 |
| Other Investing Cash Flow Items, Total | -33.6 | -160.6 | -46.8 | 16.2 | -24 |
| Cash From Financing Activities | 8.2 | -234.3 | -258.9 | -270.3 | 6.1 |
| Issuance (Retirement) of Stock, Net | 8.2 | 44.7 | 20.1 | 8.7 | 6.1 |
| Issuance (Retirement) of Debt, Net | -279 | -279 | -279 | 0 | |
| Net Change in Cash | -159.1 | -73.3 | -124 | -172.9 | -66 |
| Cash Taxes Paid | 0.2 | 14.4 | 4.3 | 3.1 | |
| Cash Interest Paid | 6.6 | 4.6 | 4.6 | ||
| Amortization | 0.9 | 0.5 | |||
| Foreign Exchange Effects | -1.3 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 10.6161 | 10366912 | 220306 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.76 | 9530883 | -26814 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.0516 | 3956499 | 156584 | 2023-06-30 | LOW |
| Bellevue Asset Management AG | Investment Advisor | 2.6756 | 2612800 | -500 | 2023-06-30 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.9547 | 1908844 | -85677 | 2023-06-30 | LOW |
| Armistice Capital LLC | Hedge Fund | 1.6897 | 1650000 | 58000 | 2023-06-30 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 1.6829 | 1643402 | -303662 | 2023-06-30 | HIGH |
| JP Morgan Asset Management | Investment Advisor | 1.6353 | 1596880 | -54369 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.56 | 1523408 | 87671 | 2023-06-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.4331 | 1399439 | 228393 | 2023-06-30 | LOW |
| Citadel Advisors LLC | Hedge Fund | 1.3377 | 1306273 | 831881 | 2023-06-30 | LOW |
| Rock Springs Capital Management LP | Hedge Fund | 1.3103 | 1279500 | 69400 | 2023-06-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 1.2666 | 1236839 | -61520 | 2023-06-30 | LOW |
| Deerfield Management Company, L.P. | Hedge Fund | 1.2388 | 1209714 | -535000 | 2023-06-30 | MED |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 1.2186 | 1190026 | -30338 | 2023-06-30 | LOW |
| Woodline Partners LP | Hedge Fund | 1.1799 | 1152189 | 753495 | 2023-06-30 | HIGH |
| American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.1308 | 1104267 | 242362 | 2023-06-30 | LOW |
| Brown Advisory | Investment Advisor/Hedge Fund | 1.1263 | 1099856 | 20963 | 2023-06-30 | LOW |
| DSM Capital Partners, LLC | Investment Advisor | 1.0858 | 1060270 | -199261 | 2023-06-30 | MED |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 1.0217 | 997725 | -47995 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Neurocrine Company profile
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.
| Industry: | Bio Therapeutic Drugs |
12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com